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year changes in the ratio were beneficially affected by lifestyle factors, but only to a mod- 
est degree. It is concerning that obesity at baseline contributes to a significant worsening 
of the ratio whereas a report of exercise only slightly improves the ratio. 
1202-88 Cholesterol Screening of Adults In the US: Role of 
Socio-demographic Factors 
(~hri~;tooher R. Bartalos, Chad Sun, Jacqueline S. Madnac, The University of Health 
Sciences, Kansas Ci~ Missouri, Medical Center of Independence, Independence, 
Missouri. 
Background: The National Cholesterol Education Program (NCEP) II & Expert Panel 
Adult Treatment Panel Ill (ATPIII) guidelines recommend a cholesterol screen every 5 
years for all adults ->20 yrs age, No information regarding the role of socio-demographic 
factors on US adult cholesterol screening has been published. 
Methods and Results: Data were extracted from the 1999 CDC Behavioral Risk Factor 
Surveillance System (BRFSS) survey. The SRFSS telephone surveyed 159,000 US 
adults regarding cholesterol screening within the last 5 years. Data were stratified by 
age, gender, ethnicity, income, education, level of insurance and the ability to afford 
health care. Overall 69% adults were screened within the last 5 yrs, which is below the 
Healthy People 2000/2010 goals of 75% & 80% respectively, However 85% adults >65 
years were screened. Adults aged _>45 years were 3.7 times more likely to receive cho- 
lesterol screening. Those with health insurance were 2.4 times more likely to receive 
screening. High school graduates or those with some college were 1.5 times more likely 
to be screened. Women were 1.2 times more likely to be screened, Those with an 
income _>$20K/yr were 1.4 times more likely to receive screening. The socio-demo- 
graphic variables had a compounding influence on cholesterol screening. For example, 
the individual <45 yrs age, who was less educated, with a lower economic status and had 
no health insurance was the least likely to report having received cholestero~ screening 
within the last 5 years (29%). 
Conclusion: Socio-demographic factors play an important role in cholesterol screening. 
This information may be used for targeted future cholesterol screening interventions. 
1202-89 Contemporary Awareness and Understanding of 
Cholesterol as a Risk Factor: Results of an American 
Heart Associat ion National Survey 
Ira S, Nash. Lori Mosca, Roger S. Blumenthal, Michael Davidson, Sidney C. Smith, 
Richard C. Pasternak, Mount Sinai School of Medicine, New York, New York. 
Public awareness and understanding of risk factors for atherosclerotic vascular disease 
are essential for successful primary and secondary prevention. The American Heart 
Association conducted a national telephone survey to assess public knowledge of the 
link between cholesterol and heart disease and the specifics of cholesterol management 
in April 2001. A national probability sample of 1114 adults age 40 years and older was 
interviewed by trained personnel using a structured format. Good regional distribution 
was achieved; 29% of respondents were over age 65, 56% were women and 87% were 
white. Most (55%) were employed and of those, 70% identified themselves as white-col- 
lar workers. Over 90% had at least a high school education and over 30% completed col- 
Ioge, Although 91% stated that it was "important o them personally to have a healthy 
cholesterol evel" (77% extremely or very important), 51% did not know their own level 
Only 40% were aware of national guidelines for cholesterol management, and 52% could 
not identify the correct desirable total cholesterol evel for a healthy adult. More people 
selected HDL than LDL as the most important lipid fraction to control (22% vs 16%). 
When asked what sources of information they rely on the most, 67% identified physicians 
and 13% stated magazines were their principal sources, while only 4% rely primarily on 
the internet. 
Conclusion: public awareness of the importance of cholesterol as a risk factor for cardio- 
vascular disease is high, but specific knowledge of cholesterol management is poor. 
Patients overwhelmingly identify physicians as their primary source of information. 
Therefore, physicians have an important opportunity to improve public understanding 
and management of lipid abnormalities, 
1202-90 Lowering LDL Cholesterol With Simvastatin, an HMG- 
CoA Reductese Inhibitor, Does Not Affect Luteal 
Function in Women 
NaDette Santoro, Diane Plotkin, Yale Mitchel, Joanna Waldstreicher, Minzhi Liu, Albert 
Einstein Col/ege of Medicine, Bronx, New York, Merck Research Laboratories, Rahway, 
New Jersey. 
Background: Cholesterol is the precursor of all steroid hormones, therefore cholesterol- 
reducing drugs could theoretically disrupt gonadal function in premenopausal women. 
Methods: This double-blind, randomized, placebo-controlled study was conducted to 
evaluate the effects of simvastatin treatment in premenopausal women. Normally cycling 
women (n=86) with elevated baseline LDL cholesterol (LDL-C) levels (130-250 mg/dL) 
were studied over six menstrual cycles. At the end of the screening phase (cycle #1), 
participants received placebo for the second menstrual cycle, and subsequently were 
randomized to receive either placebo (n=44) or simvastatin 40 mg/day (n=42) for the next 
four menstrual cycles (cycle #3-6). The second and sixth menstrual cycles were consid- 
ered baseline and treatment cycles, respectively. Participants kept a menstrual diary 
throughout he study, recording onset and duration of bleeding, and provided daily first- 
void urine samples (cycles #2 and 6). Urine samples were assayed for lutonizing hor- 
mone (LH) and pregnanediol glucuronide (PdG), the chief urinary metabolita of progest- 
erone. The primary endpoint was change in luteal phase duration as defined by the day 
of the urinary LH peak to the day preceding the onset of menstruation. The primary 
hypothesis was that there would not be a clinically significant decrease (4 days) in luteal 
phase duration between the treatment groups. 
Results'. Simvastatin Iowerad LDL-C and triglycerides by 34.3 (p<0.001) and 14.7% 
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(p<0.001), respectively, and raised high-density lipoprotein cholesterol by 4.9% 
(p<0.050). Simvastatin treatment had no clinically relevant effect on luteal phase dura- 
tion, peak PdG concentration, or integrated lutaal phase PdG concentration compared to 
the placebo group. Furthermore, the number of women experiencing anovulatory cycles 
or abnormal cycle lengths did not differ between the treatment groups. 
Conclualon: Treatment with simvastatin 40 mg/day was safe and effective at Iowedng 
LDL-C and did not adversely affect the hypothalamic-pituitary-gonadal axis in premeno- 
pausal women. 
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873-1 Lack of Association of Celecoxib With an Increased 
Risk of Thromboembollc Events 
Gerald Faich. l, E. Allen, S. D, Ross, James B. Lafkowith, Pharmaceutical Safety 
Assessments, Inc., Narberth, Pennsylvania, Metaworks, Inc., Medford, Massachusetts. 
Background: It has been hypothesized that COX-2 specific inhibitors may increase the 
risk of cardiovascular (CV) thromboembolic events because of their inhibition of vascular 
prostacyclin synthesis and lack of an effect on platelet aggregation. 
Methods: Data from the celecoxib clinical trial database were analyzed to deteEmine the 
incidence of sedous thromboembolic events (cardiac, cerebrovascular and peripheral 
vascular events) using a methodology derived from a recent FDA cardiorenal review 
(NDA 21-042, S-007). Since aspirin use for CV prophylaxis (<325 rag/d) was permitted, 
the analysis was performed for all patients and patients not taking aspirin, 
Results: The incidence rates, patient exposure and relative risk (RR) for the long term 
safety trial CLASS (duration 12-15 rod.), 15 controlled arthritis trials (durations 3-6 rod.) 
and the open label long term safety trial (duration 24-36 mo.) for celecoxib and NSAIDs 
(naproxen, diclofenac, ibuprofen) are shown in the following table (unadjusted for differ- 
ences in study demographics and cardiac risk factors). 
Conclusion: These data suggest that celecoxib is not associated with an increased inci- 
dence of serious thromboembolic events when compared to NSAIDs and thus do not 
support the hypothesis of a class effect of COX-2 specific inhibitors on CV events. 
Disclosure: Sponsored by Pharmacia Corporation and Pfizer Inc. 
Celecoxib NSAIDs RR (95% CI) 
CLASS Rate/100 pt-yrs (total patient exposure) 
All Patients 2.24 (2,320) 
Non-ASA 1.39 (1,804) 
Adhdtis Trials 
All 1.41 (2,845) 
Non-ASA 0.73 (2,587) 
Open Label Trial 
All 1.37 (7,024) 
Non-ASA 0.80 (5,720) 
2.22 (2,203) 1.01 (0.67-1.52) 
1.34 (1,715) 1.03 (0.56-1.91) 
1.59 (1,445) 0.88 (0.52-1.55) 
1.21 (1,325) 0.61 (0.30-1.26) 
Combined Trials (CLASS, Arthritis, Open Label) 
All 1.59 (11,693) 1.97 (3,648) 0.61 (0.61-1.07) 
Non-ASA 0.92 (9,677) 1.28 (3,040) 0.72 (0.49-1.07) 
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873-2 Ominous Prognostic Implications and Inadequacy of 
Heparin Alone for Right Heart Thrombi in Patients With 
Acute Pulmonary Embolism: Analysis of Baseline 
Characteristics, Echocardiograms, Treatment, and 
Clinical Outcomes in the International Cooperative 
Pulmonary Embolism Registry 
Adam Torbicki, Samuel Z. Gctdhaber. Nazzareno Gali6, Anna Covezzoli, Madse De 
Rosa, on behalf of the ICOPER Study Group, Institute of Tuberculosis and Lung Disease, 
Warsaw, Poland. 
Background: Management of right heart thrombi (RHTh) in acute pulmonary embolism 
(PE) is controversial, because most reports have been small case series. Therefore, we 
analyzed 2, 454 consecutive acute PE patients enrolled in International Cooperative Pul- 
monary Embolism Registry (ICOPER). 
Methods: Of the 2,454 patients, 1,143 underwent baseline echocardiography. We com- 
pared the 42 patients with versus 1,071 without RHTh. 
Result,,: Patients with RHTh had lower systolic blood pressure (116.0.+_28.0 versus 
125.7..1:25.0 mmHg, p=0.008), especially < 90 mm Hg (14% versus 5%, p=0.012), and 
more frequent right ventdcular hypokinesis (64% versus 40%, p=0.002). However, they 
were similar at admission with respect to age (62.9 versus 62.5 years), arterial oxygen 
pressure (71.3+26.0 versus 69.5+30.5 mmHg), and prevalence of cancer (14% versus 
19%). The overall mortality rate at 14 days and at 3 months was twice as high in patients 
with RHTh (21% versus 11%, and 29% versus 16%, respectively, p<0.06) and remained 
so after the exclusion of patients with right heart catheters and electrodes potentially pro. 
